OBJECTIVE

Seeking a scientist position in the Medical Research where 10 years of R&D

in molecular biology and clinical data management experience will add

value.

QUALIFICATIONS SUMMARY

* Proven history of solid research in designing and executing cell based

and ELISA assays in support of pre-clinical and toxicology studies in

preparation for IND filings.

* Follow multiple and different experimental designs with great

attention to details.

* Extensive molecular biology technical skills are supportive of pre-

clinical and toxicology studies.

* Self-motivated scientist with ability to work in multiple projects

EXPERIENCE HIGHLIGHTS

Synteract, Inc., Carlsbad, CA 2008

to 2010

Clinical Data coordinator:

Follow GCP requirements per FDA regulations and ICH guidelines. Development

of data management plans and QA programs for sponsor approvals. Review

data, write and resolve queries. Conduct start up activities for new

studies. Develop, maintain and document data entry guidelines and data

conventions. Research information and prepare written documents. Experience

with variety of Electronic Data Capture (EDC), such as IDataFax and

Clintrial. Communicate clearly and precisely, both orally and in writing.

Identify problems and effectively offer solutions. Work on multiple tasks

simultaneously and meet project timelines.

TargeGen, Inc, Oncology Department, San Diego, CA, 2004

to 2008

Research Associate IV:

Extensive experience in cell based and ELISA assays for the determination

of the candidate drugs on certain targets in cell pathways. Vast experience

with biomarker assays in support of drug efficacy and specificity studies.

Development of clinical biomarkers for biocompatibility studies in support

of IND filing. Managed data analysis received from outside vendors and

collaborators in determining drug specificity and potency in different

signaling pathways. Generated resistant cell lines to specific drugs.

Demonstrated effectiveness in management of external collaborations and

outsourcing

(Leadership role in performing Cell Prime Collagen Gels assay to determine

certain drug efficacy and specificity.

(Implemented a new drug-screening assay using a new technology Fluorescence

Resonance Energy Transfer (FRET) in in-vitro. The new technology decreased

the turn around time spent in drug screening from 5-days to 1-day.

(Leadership role in developing Biomarker assays to determine drug

specificity and selectivity in JAK/ stat signaling Pathway.

(Responsible for developing novel FITC Lectin-Matrigel assay in screening

native fluorescence compounds in 96 well formats.

(Presented TargeGen in American Association of Cancer Research conference

(AACR) in 2006.

Genomic institute of the Novartis Foundation, San Diego, CA 2003

to 2003

Research Associate III:

Developed assays for novel drug targets using Fluorescence Polarization

(FP) for the HIV project. Studied the effect of different buffer conditions

on the activity of HIV integrase.

(Determined the activity of HIV integrase using a cost effective technique.

EXPERIENCE HIGHLIGHTS (cont'd)

NewBiotics, Inc., Oncology Department, San Diego, CA 2001

to 2003

Research Associate II:

Leadership role in managing screening assays including XTT, apoptosis, and

mycoplasma assays. Leadership role in programming the fluidic robotic

(Multi- Probe II) to perform various cell based assays. Developed new

protocol for drug screening in cell based assay and performed data

analysis. Maintained mammalian and tumor cell lines. Presented technical

reports to upper managements.

(Optimized the turn around time of cell screening assays.

(Provided management with timely supportive data of structural design for

further investigational in in-vivo studies.

INOVA Diagnostics, Inc, San Diego, CA 2000

to 2001

Production Chemist II:

Successfully performed the isolation and purification of Human Neutrophil

for ANCA diagnostic kit following FDA regulations and internal company

SOPs. Excelled in staining and fixating mammalian tissue. Leadership role

in implementing stability testing under various conditions.

PROFESSIONAL DEVELOPMENT/COMPUTER SKILLS

(Biological safety level 3 training, Radiation safety Certification, animal-

handling, VAMRF, San Diego, CA.

(Sigma plot 8.0 programs for data analysis, interpretation, and graphic

applications.

EDUCATION

(Masters of Sciences, Chemistry-Biochemistry, San Diego State University,

2001.

(Bachelors of Sciences, Biology-Biochemistry, Ain-Shams University, 1993.

(Pharmacokinetics (Winter 2007), Medical Terminology (Spring 2007), Medical

Writing (Fall 2008), University of California San Diego.

(Public Speaking (Fall 2004), Macroeconomic(Summer 2004), Psychology(Fall

2008), and Business Development (Summer 2009), Sociology (Fall 2009),

Miramar Community College.

PUPLICATIONS

1. P. Saylor, Ehab Hanna, and J. A. Adams, "Mutations in the Activation

Loop Tyrosine of the Oncoprotein, v-Fps". Biochemistry. 1998; 37, 17875.

2. Hanna, E., Zhu, H., Lohse, D., Stoughton, S., Tam, B., Barrett, K.,

Noronha, G., Dneprovskaia, E., Cao, J., Chow, C., Hwang, L., Mak, C.,

McPherson, A., Palanki, M., Pathak, V., Renick, J., Soll, R., Zeng, B.,

Hood, J., Jamieson, K., Postdoc, "In vitro and in vivo Inhibition of the

T315I Mutant BCR/Abl Kinase". TargeGen, Inc., San Diego, CA92121, USA

Moore Cancer Center, UC San Diego, CA92121, USA.

3. "Anti -Tumoral activity of noval Jak2 kinase inhibitor in acute myeloid

leukemia harboring FLT3 -activating mutations", AACR poster 2006.

4. Glynn Noronha, Kathy Barrett, Antonio Boccia, Tessa Brodhag, Jianguo

Cao, Chun P. Chow, Elena Dneprovskaia, John Doukas, Richard Fine,

Xianchang Gong, Colleen Gritzen, Hong Gu, Ehab Hanna, John D. Hood,

Steven Hu, Xinshan Kang, Jann Key, Boris Klebansky, Ahmed Kousba, Ge Li,

Dan Lohse, Chi Ching Mak, Andrew McPherson, Moorthy S.S. Palanki, Ved P.

Pathak, Joel Renick, Feng Shi, Richard Soll, Ute Splittgerber, Silva

Stoughton, Suhan Tang, Shiyin Yee, Binqi Zeng, Ningning Zhao, Hong Zhu,

"Discovery and preliminary structure activity relationship studies of

novel benzotriazine based compounds as Src inhibitors". Organic &

Medicinal Chemistry Letters. Nov 1, 2006; 16(21): 5546-5550.

5. Glenn Noronha, Kathy Barrett, Antonio Boccia, Tessa Brodhag, Jianguo

Cao, Chun P. Chow, Elena Dneprovskaia, John Doukas, Richard Fine,

Xianchang Gong, Colleen Gritzen, Hong Gu, Ehab Hanna, John D. Hood,

Steven Hu, Xinshan Kang, Jann Key, Boris Klebansky, Ahmed Kousba, Ge Li,

Dan Lohse, Chi Ching Mak, Andrew McPherson, Moorthy S.S. Palanki, Ved P.

Pathak, Joel Renick, Feng Shi, Richard Soll, Ute Splittgerber, Silva

Stoughton, Suhan Tang, Shiyin Yee, Binqi Zeng, Ningning Zhao, Hong Zhu,

"Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-

[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine - a potent, orally active src

kinase inhibitor with anti-tumor activity in preclinical assays".

Bioorganic and Medicinal Chemistry Letters. 2007 Feb 1; 17 (3): 602-8.

6. Moorthy S. S. Palanki, Jianguo Cao, Zoe Chen, Chun P. Chow, Luis

Dellamary, John Doukas, Ehab Hanna, John Hood, Ahmed Kousba, Dan Lohse,

Chi Ching Mak, Sankaranarayana Mahesh, Michael Martin, Andrew McPherson,

"TG100801: Development of SRC/VEGFr2/YES Inhibitor for the Treatment of

Age-Related Macular Degeneration". Journal of Medicinal Chemistry. 2008

March 27; 51(6):1546-59.

Contact this candidate